目的探讨Beta-adducin（Add2）基因的rs3755351单核苷酸多态性与福建和广东人群中高血压发病的相关性。方法应用MassARRAY-IPLEX技术和基质辅助激光解吸电离飞行时间质谱平台（Matrix-assisted laser desorption/ionization time of fig...目的探讨Beta-adducin（Add2）基因的rs3755351单核苷酸多态性与福建和广东人群中高血压发病的相关性。方法应用MassARRAY-IPLEX技术和基质辅助激光解吸电离飞行时间质谱平台（Matrix-assisted laser desorption/ionization time of fight mass spectrometry,MALDI-TOF-MS）对广东和福建940例高血压患者和944名健康查体者对照进行Add2基因rs3755351位点的基因分型。用χ2检验统计分析病例组和对照组基因型和等位基因的频率;采用非条件Logistic回归分析,计算比值比（OR）和95%CI,评价多态性位点与高血压遗传易感性的相关性。结果 Add2基因rs3755351多态位点有AA,AC和CC三种基因型,在隐性模型中,Add2基因的rs3755351多态位点AA、AC-CC基因型在福建高血压人群中的分布频率为10.5%和89.5%,与对照组（14.2%、85.8%）相比差异有统计学意义（P〈0.05）,与AC或CC基因型相比,携带AA基因型能显著降低患高血压的发病危险（OR=0.65,95%CI：0.43~0.99,P=0.044）;rs3755351的AA、AC和CC基因型在广东高血压人群中的分布频率为15.1%、53.0%和31.8%,与对照组（12.4%、52.4%和35.2%）相比差异无统计学意义（P〉0.05）。结论 Add2基因的rs3755351多态位点与福建人群的高血压遗传易感性相关,与AC或CC基因型相比,携带AA基因型能显著降低患高血压的发病危险;rs3755351在广东人群中未发现与高血压的遗传易感性相关。展开更多
Objective: To assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract(IND-2) add-on therapy in type 2 diabetes mellitus(T2DM) patients who were on insulin treatment in prospect...Objective: To assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract(IND-2) add-on therapy in type 2 diabetes mellitus(T2DM) patients who were on insulin treatment in prospective, single arm, open-label, uncontrolled, multicentre trial.Methods: T2DM patients(n=30) with aged 18-80 years who were stabilized on insulin treatment with fasting blood sugar(FBS) level between 100-140 mg/dL received IND-2 capsules(700 mg, thrice a day) for 16 weeks.The primary endpoints were an assessment of FBS at week 2, 4, 6, 8, 12 and 16.Secondary end-points include post-prandial blood sugar level, glycosylated Hb(HbA1c), reduction in the dose of insulin and number of hypoglycemic attacks, and improvement in lipid profile at various weeks.Safety and adverse events(AEs) were also assessed during the study.Results: Study was completed in twenty T2DM patients, and there was no significant reduction in FBS and post-prandial blood sugar level after addon therapy of IND-2.However, add-on therapy of IND-2 significantly reduced(P<0.01) the HbA1c values, requirements of insulin and hypoglycemic events as compared with baseline.Total cholesterol, high-density lipoproteins-cholesterol, and low-density lipoproteincholesterol levels were significantly increased(P<0.01) after IND-2 add-on therapy.Body weight and safety outcomes did not differ significantly in IND-2 add-on therapy group at week 16.Additionally, add-on therapy of IND-2 did not produce any serious adverse events.Conclusions: The results of present investigation suggest that add-on therapy of IND-2 with insulin in T2DM patients improves glycaemic control through a decrease in levels of HbA1c and number of insulin doses needed per day without an increase in body weight and risk of hypoglycemia.Thus, IND-2 may provide a safe and well-tolerated add-on therapy option for the management of T2DM.展开更多
以升华物质2,4,6-三异丙基-1,3,5-三氧杂环己烷(ADD)为造孔剂,制备聚苯胺(PANI)包覆的中空核-壳结构硫复合物S@(ADD)@PANI。在化学制备的硫微粒上依次逐层包覆ADD和PANI,再在60℃下加热,使ADD挥发,制得S@(ADD)@PANI。SEM、透射扫描电镜(...以升华物质2,4,6-三异丙基-1,3,5-三氧杂环己烷(ADD)为造孔剂,制备聚苯胺(PANI)包覆的中空核-壳结构硫复合物S@(ADD)@PANI。在化学制备的硫微粒上依次逐层包覆ADD和PANI,再在60℃下加热,使ADD挥发,制得S@(ADD)@PANI。SEM、透射扫描电镜(TEM)和热重分析(TG)分析表明,制得的S@(ADD)@PANI的粒径约为1μm,硫含量为70. 7%。S@(ADD)@PANI的电化学性能优于化学制备硫。以200 m A/g的电流在1. 5~2. 8 V充放电,首次放电比容量为921 m Ah/g,第100次循环的放电比容量为500 m Ah/g。在相同的放电制度下,化学制备的硫电极的首次放电比容量为1 032. 4 m Ah/g,但稳定性差,第2次循环时的放电比容量就低于S@(ADD)@PANI,第100次循环的放电比容量下降到221. 9 m Ah/g。展开更多
文摘目的探讨Beta-adducin（Add2）基因的rs3755351单核苷酸多态性与福建和广东人群中高血压发病的相关性。方法应用MassARRAY-IPLEX技术和基质辅助激光解吸电离飞行时间质谱平台（Matrix-assisted laser desorption/ionization time of fight mass spectrometry,MALDI-TOF-MS）对广东和福建940例高血压患者和944名健康查体者对照进行Add2基因rs3755351位点的基因分型。用χ2检验统计分析病例组和对照组基因型和等位基因的频率;采用非条件Logistic回归分析,计算比值比（OR）和95%CI,评价多态性位点与高血压遗传易感性的相关性。结果 Add2基因rs3755351多态位点有AA,AC和CC三种基因型,在隐性模型中,Add2基因的rs3755351多态位点AA、AC-CC基因型在福建高血压人群中的分布频率为10.5%和89.5%,与对照组（14.2%、85.8%）相比差异有统计学意义（P〈0.05）,与AC或CC基因型相比,携带AA基因型能显著降低患高血压的发病危险（OR=0.65,95%CI：0.43~0.99,P=0.044）;rs3755351的AA、AC和CC基因型在广东高血压人群中的分布频率为15.1%、53.0%和31.8%,与对照组（12.4%、52.4%和35.2%）相比差异无统计学意义（P〉0.05）。结论 Add2基因的rs3755351多态位点与福建人群的高血压遗传易感性相关,与AC或CC基因型相比,携带AA基因型能显著降低患高血压的发病危险;rs3755351在广东人群中未发现与高血压的遗传易感性相关。
文摘Objective: To assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract(IND-2) add-on therapy in type 2 diabetes mellitus(T2DM) patients who were on insulin treatment in prospective, single arm, open-label, uncontrolled, multicentre trial.Methods: T2DM patients(n=30) with aged 18-80 years who were stabilized on insulin treatment with fasting blood sugar(FBS) level between 100-140 mg/dL received IND-2 capsules(700 mg, thrice a day) for 16 weeks.The primary endpoints were an assessment of FBS at week 2, 4, 6, 8, 12 and 16.Secondary end-points include post-prandial blood sugar level, glycosylated Hb(HbA1c), reduction in the dose of insulin and number of hypoglycemic attacks, and improvement in lipid profile at various weeks.Safety and adverse events(AEs) were also assessed during the study.Results: Study was completed in twenty T2DM patients, and there was no significant reduction in FBS and post-prandial blood sugar level after addon therapy of IND-2.However, add-on therapy of IND-2 significantly reduced(P<0.01) the HbA1c values, requirements of insulin and hypoglycemic events as compared with baseline.Total cholesterol, high-density lipoproteins-cholesterol, and low-density lipoproteincholesterol levels were significantly increased(P<0.01) after IND-2 add-on therapy.Body weight and safety outcomes did not differ significantly in IND-2 add-on therapy group at week 16.Additionally, add-on therapy of IND-2 did not produce any serious adverse events.Conclusions: The results of present investigation suggest that add-on therapy of IND-2 with insulin in T2DM patients improves glycaemic control through a decrease in levels of HbA1c and number of insulin doses needed per day without an increase in body weight and risk of hypoglycemia.Thus, IND-2 may provide a safe and well-tolerated add-on therapy option for the management of T2DM.
文摘以升华物质2,4,6-三异丙基-1,3,5-三氧杂环己烷(ADD)为造孔剂,制备聚苯胺(PANI)包覆的中空核-壳结构硫复合物S@(ADD)@PANI。在化学制备的硫微粒上依次逐层包覆ADD和PANI,再在60℃下加热,使ADD挥发,制得S@(ADD)@PANI。SEM、透射扫描电镜(TEM)和热重分析(TG)分析表明,制得的S@(ADD)@PANI的粒径约为1μm,硫含量为70. 7%。S@(ADD)@PANI的电化学性能优于化学制备硫。以200 m A/g的电流在1. 5~2. 8 V充放电,首次放电比容量为921 m Ah/g,第100次循环的放电比容量为500 m Ah/g。在相同的放电制度下,化学制备的硫电极的首次放电比容量为1 032. 4 m Ah/g,但稳定性差,第2次循环时的放电比容量就低于S@(ADD)@PANI,第100次循环的放电比容量下降到221. 9 m Ah/g。
